Our study was designed to evaluate a population endpoint (egg production) in conjunction with histological (e.g., gonad development) and biochemical (e.g., hormone production) phenotypes associated with atrazine exposure in fathead minnows.
The present study was designed to evaluate a population endpoint (egg production) in conjunction with histological (reproductive stage, gonad pathology) and biochemical (aromatase activity, sex hormone production) phenotypes associated with atrazine exposure in Japanese medaka.
The single-cell population endpoint measurements could also be obtained using other technologies, including two-color flow cytometry.
As others have noted, chronic exposure of D. pulex to cadmium reduced individual fitness parameters, such as length and lipid-ovary indices, and inhibited population endpoints, such as number of clutches, cumulative reproduction, and per capita birth rate (Table 1; [ 55, 56]).
The placebo-controlled trials of these oral MS therapies are not sufficiently similar and differences between the trials, including differences in patient populations, endpoint definitions and methods for dealing with non-completers, have not been taken into account in any of the NMAs of these therapies performed to date.
While there were differences in NOAC study design and dosing regimens, enrollment criteria, population, and endpoint measures, ultimately outcomes were comparable.
The objective of the study was to investigate the efficacy and safety of hexaminolevulinate (HAL) photodynamic therapy (PDT), a novel therapy for women with cervical intraepithelial neoplasia (CIN 1/2, to define the appropriate population and endpoints for a phase 3 program.
In this homogeneous population, PK endpoints can be fairly consistent.
Even when trials are published, the study population, primary endpoints, and results can differ substantially from data submitted to the FDA.
The cells were incubated with 10 μM of AA in serum-free medium for 24 h and then treated with 5 μM of calcein AM for 30 min to stain the cell populations in endpoint assays.
Clinical trials for biosimilar mAbs must be carried out in an appropriately sensitive patient population using endpoints that can accurately demonstrate both the similarity of the biosimilar and its efficacy in the indication.
